There are about 173942 clinical studies being (or have been) conducted in United States. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The study format is a prospective non-randomized study to be conducted at a single site. Up to twenty consecutive DFLBP patients meeting the inclusion and exclusion criteria and who provide informed consent will be enrolled in the study. The patients will receive treatment compliant with national guidelines. Appropriate patients will be injected with 0.5cc of ExoFlo into each of their affected facet joint(s). The facets to be treated will be determined by imaging and Dr. Wilson. Up to three vertebral levels can be treated. Patients will be assessed with pre and post-treatment physical examination. At baseline, Brief Pain Inventory (BPI) and Visual Analogue Scale (VAS) will be documented. BPI and VAS scoring will be collected at 24 hours, 3 days, 7 days, 1 month, 2 months and 3 months after each treatment. Adverse events will be monitored by follow-up phone calls at 24, 48 hours, 1 week after the procedure and at all follow-up visits. Patients drug usage will be monitored. Patient will be instructed to call the office any time after treatment if they are experiencing any adverse events. A patient can leave the study at any time.
This is a Phase 1, randomized, double-blind, vehicle-controlled, SAD / MAD study evaluating three dose levels of PBI-100 topical cream in healthy adult volunteers and/or subjects with psoriasis.
In this current study, the examiners examine some of the mechanisms of how Acute Intermittent Hypoxia (AIH) effects the upper extremity of survivors of spinal cord injury. This is accomplished both with the use of a load cell to determine elbow strength changes and high density grid electromyography (EMG) to record bicep muscle activations before and after bouts of AIH
To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.
The investigators propose to compare the effects of a 16-week specially designed yoga program to a power-based resistance training program on affect trait mindfulness, anxiety, depression, functionality, and quality of life. As secondary measures, we propose to compare the effects of these exercise programs on measures of executive function (EF), sleep, disease stage, motor symptoms, muscle quality, rigidity, strength, power, and mobility.
The investigators propose to compare the effects of a 12-week load resistance training program to a velocity resistance training program on ultrasound measures of quadriceps muscle quality in a healthy, older adult population. As secondary measures, The investigators propose to compare the effects of these exercise programs on maximal strength, power, and functional movements such as the chair sit-to-stand and gait speed. Further, The investigators will evaluate the impact of each protocol on cognitive function.
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile of RIV4 in all participants.
The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas' PsO Registry under routine medical care initiating secukinumab (SEC).
The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.
This study will assess the pharmacokinetics of AZD5462 film-coated tablet formulation in healthy participants.